194 related articles for article (PubMed ID: 15885828)
1. Economic evaluation of proton radiation therapy in the treatment of breast cancer.
Lundkvist J; Ekman M; Ericsson SR; Isacsson U; Jönsson B; Glimelius B
Radiother Oncol; 2005 May; 75(2):179-85. PubMed ID: 15885828
[TBL] [Abstract][Full Text] [Related]
2. Proton therapy of cancer: potential clinical advantages and cost-effectiveness.
Lundkvist J; Ekman M; Ericsson SR; Jönsson B; Glimelius B
Acta Oncol; 2005; 44(8):850-61. PubMed ID: 16332592
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma.
Lundkvist J; Ekman M; Ericsson SR; Jönsson B; Glimelius B
Cancer; 2005 Feb; 103(4):793-801. PubMed ID: 15637691
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast.
Suh WW; Hillner BE; Pierce LJ; Hayman JA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1054-61. PubMed ID: 15752884
[TBL] [Abstract][Full Text] [Related]
6. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of sevelamer in patients with end-stage renal disease.
Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
[TBL] [Abstract][Full Text] [Related]
8. The potential of proton beam radiation therapy in breast cancer.
Björk-Eriksson T; Glimelius B
Acta Oncol; 2005; 44(8):884-9. PubMed ID: 16332597
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
10. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
Naeim A; Keeler EB
Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10).
Konski A; Sherman E; Krahn M; Bremner K; Beck JR; Watkins-Bruner D; Pilepich M
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):788-94. PubMed ID: 16109464
[TBL] [Abstract][Full Text] [Related]
13. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?
Konski A; Speier W; Hanlon A; Beck JR; Pollack A
J Clin Oncol; 2007 Aug; 25(24):3603-8. PubMed ID: 17704408
[TBL] [Abstract][Full Text] [Related]
14. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer.
Konski A; Watkins-Bruner D; Feigenberg S; Hanlon A; Kulkarni S; Beck JR; Horwitz EM; Pollack A
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):408-15. PubMed ID: 16887291
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women.
Taneja C; Edelsberg J; Weycker D; Guo A; Oster G; Weinreb J
J Am Coll Radiol; 2009 Mar; 6(3):171-9. PubMed ID: 19248993
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen for breast cancer prevention: a framework for clinical decisions.
Cykert S; Phifer N; Hansen C
Obstet Gynecol; 2004 Sep; 104(3):433-42. PubMed ID: 15339751
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data.
Hjelmgren J; Svensson A; Jörgensen ET; Lindemalm-Lundstam B; Ragnarson Tennvall G
Br J Dermatol; 2007 May; 156(5):913-21. PubMed ID: 17263826
[TBL] [Abstract][Full Text] [Related]
18. CHART in lung cancer: economic evaluation and incentives for implementation.
Lievens Y; Kesteloot K; Van den Bogaert W
Radiother Oncol; 2005 May; 75(2):171-8. PubMed ID: 15878631
[TBL] [Abstract][Full Text] [Related]
19. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons.
Peeters A; Grutters JP; Pijls-Johannesma M; Reimoser S; De Ruysscher D; Severens JL; Joore MA; Lambin P
Radiother Oncol; 2010 Apr; 95(1):45-53. PubMed ID: 20106540
[TBL] [Abstract][Full Text] [Related]
20. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
